BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
NCT01297452
Completed
The purpose of this study is to find out the good and bad effects that occur when BKM120 is added to standard chemotherapy with carboplatin and paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2017
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Solid Tumors
Register for Updates
Surgery in Treating Children With Neuroblastoma
NCT00003119
Completed
RATIONALE: Surgery alone may be effective in treating children with neuroblastoma. PURPOSE: Phase III trial to study the effectiveness of surgery alone in treating children who have neuroblastoma.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
03/09/2017
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +234 locations
Conditions: Neuroblastoma
Register for Updates
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
NCT00976573
Completed
This randomized phase II trial is studying how well carboplatin, paclitaxel, and bevacizumab work when given with or without everolimus in treating patients with malignant melanoma that has spread from where it started to other places in the body. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may block the ability o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2017
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +309 locations
Conditions: Melanoma (Skin)
Register for Updates
Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00874107
Completed
The Phase 2 study described in this protocol will serve to evaluate the antitumor activity, safety and pharmacokinetic profile of Imprime PGG when combined with bevacizumab and concomitant paclitaxel and carboplatin therapy in patients with previously untreated advanced NSCLC. Additionally, this study will provide guidance for the design of more definitive efficacy studies of Imprime PGG in NSCLC patients.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/01/2017
Locations: Highlands Oncology Group, Fayetteville, Arkansas +9 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
NCT00513383
Completed
This study is being done to test whether panitumumab, in combination with chemotherapy and radiation is safe in people with head and neck cancer. Another goal of this study is to find the highest dose of the study drugs that can be given safely without causing serious sife effects. Panitumumab is a type of drug called a monoclonal antibody that has been studied in other types of cancers, such as kidney and colon. This monoclonal antibody is directed against the epidermal growth factor receptor (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2017
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma
NCT02437812
Unknown
Initially, the prospect of metformin as a neoplastic treatment was considered for malignancies of the prostate, colon and pancreas. However, only select clinical studies involving the use of metformin in the treatment of ovarian cancer have documented improved survival rates. Since no first line regimen has demonstrated compelling superiority in the management of advanced stage ovarian carcinoma, the combination of paclitaxel, carboplatin, and metformin is of particular interest given the triple... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/24/2017
Locations: Gynecologic Oncology Associates, Newport Beach, California
Conditions: Epithelial Ovarian Carcinoma
Register for Updates
Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer
NCT00642759
Completed
The purpose of this research study is to learn more about whether the combination of drugs carboplatin, Abraxane and Avastin helps treat non-small cell lung cancer (NSCLC). One of the standard treatments for advanced NSCLC is the combination of the drugs carboplatin, paclitaxel and Avastin. Paclitaxel can be associated with severe side effects that may make the treatment difficult to tolerate. Some of these side effects are caused by the solution used to dissolve paclitaxel before it can be admi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2017
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors
NCT00607048
Completed
This is a dose-finding study; therefore, there is no hypothesis testing
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/22/2017
Locations: Pfizer Investigational Site, Los Angeles, California +3 locations
Conditions: Neoplasms
Register for Updates
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
NCT01493505
Terminated
The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/22/2017
Locations: Research Site, Birmingham, Alabama +309 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Register for Updates
The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
NCT00215930
Completed
The standard treatment for non-small cell lung cancer, stage IV or IIIB malignant pleural effusion is chemotherapy. The decision to use a regimen is currently determined by toxicity or by physician's preference. In this protocol, the treatment regimen will be assigned based on the patients' tumor molecular profile. A tumor molecular profile analysis will allow the physician to define a specific molecular portrait that shows the genetic basis of the tumor. This analysis results in a detailed repo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2017
Locations: H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC
NCT00226590
Completed
This is a single institution Phase II study for patients with unresectable Stage IIIA and IIIB non-small cell lung cancer. The treatment started with 2 cycles of gemcitabine and carboplatin followed by concurrent chemotherapy with radiation. The chemoradiation included using paclitaxel and carboplatin with daily thoracic radiation to a total dose of 74 Gy. Response rate was determined following the chemotherapy with gemcitabine and carboplatin and evaluated again after the chemoradiation. Treatm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2017
Locations: H. Lee Moffitt Cancer Center & Research Insitute, Tampa, Florida
Conditions: Lung Cancer
Register for Updates
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
NCT00604461
Terminated
The purpose of this research study was to evaluate how effective the combination of Carboplatin, Bevacizumab (Avastin™) and, Pemetrexed (Alimta™) is in the treatment of patients with Malignant Pleural Mesothelioma (MPM). A combination of cisplatin and pemetrexed is considered standard for this disease and typically off protocol patients would receive cisplatin or carboplatin and pemetrexed as standard of care. The planned length of the study (first patient screened to last patient enrolled) was... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2017
Locations: H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
Conditions: Mesothelioma
Register for Updates